查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049581

抗生素市場規模、佔有率、趨勢和預測：按作用機制、藥物類別、抗菌頻譜、給藥途徑、最終用戶和地區分類，2026-2034 年

Antibiotics Market Size, Share, Trends and Forecast by Action Mechanism, Drug Class, Spectrum of Activity, Route of Administration, End User, and Region, 2026-2034
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

2025年全球抗生素市場規模為550億美元。預計到2034年，該市場規模將達到743億美元，2026年至2034年的複合年成長率（CAGR）為3.28%。目前，亞太地區是該市場的主要驅動力，預計2025年將佔據44%的市場佔有率。肺炎、結核病和其他感染疾病病例的不斷增加推動了該市場的成長。人們對抗菌素抗藥性的日益關注正在加速開發更有效的新型抗生素療法。發展中地區醫療保健覆蓋範圍的擴大也促進了抗生素消費量的成長。此外，生物技術和藥物研發領域的持續進步也是推動抗生素市場佔有率擴張的關鍵因素。

目前，全球慢性病盛行率的不斷上升正在推動市場成長。此外，線上線下通路抗生素供應的日益充足，以及外用抗生素需求的成長，也促進了產品需求。抗生素有助於降低手術傷口感染的風險，這推動了全球對抗生素的需求。為保障牲畜健康和福利而增加的抗生素使用也促進了市場成長。此外，消費者預防醫學意識的提高以及人口老化帶來的日益成長的需求，也支持抗生素市場的成長。

受持續不斷的細菌感染疾病治療需求和日益嚴重的抗生素抗藥性問題的推動，美國抗生素市場正經歷強勁成長。對研發的投資和政府主導的各項措施正在加速開發更有效的治療方法。一個值得關注的例子是Zevtera（頭孢吡肟/美卡利鈉注射液），該藥於2023年4月獲得美國食品藥物管理局（FDA）核准。此藥用於治療金黃色葡萄球菌引起的血流感染疾病（菌血症），包括右心感染性心內膜炎和急性細菌性皮膚感染疾病。

抗生素市場趨勢：

感染疾病率增加

在全球範圍內，肺炎、肺結核、尿道感染、胃腸道感染疾病和血液系統膿毒症等感染疾病的發生率正在上升，而衛生條件差加劇了人們患有這些疾病的痛苦。這助長了細菌感染疾病的傳播。每25名女性中就有10名，每25名男性就有3名，一生中會在某個階段經歷尿道感染。治療這些感染疾病需要使用更強效的抗生素。抗生素是專門針對並清除細菌感染疾病而設計的。它們能有效殺死體內的細菌，促進癒合。此外，抗生素的使用也需在醫療專業人員的指導下進行，以最大限度地提高患者的治療效果。

抗菌素抗藥性（AMR）的增加

全球範圍內抗菌素抗藥性（AMR）的日益普遍正在推動抗生素市場的成長。當細菌、病毒、寄生蟲或真菌進化並獲得對治療藥物的抗藥性時，就會發生抗菌素抗藥性。這會降低抗生素的療效，導致感染疾病持續時間延長、病情加重、醫療成本增加、死亡率上升。 2019年，全球有127萬人死於細菌抗菌素抗藥性。抗生素的過度使用和濫用會導致抗藥性細菌的產生，從而降低傳統抗生素的療效。此外，抗甲氧抗藥性金黃色葡萄球菌（MRSA）和耐碳青黴烯類腸桿菌科細菌（CRE）等多重抗藥性細菌的傳播也不斷加劇。這促使人們需要銷售和研發更先進的抗生素，進而推動市場成長。

抗生素技術的進步

生物技術、分子生物學和藥物發現技術的創新正在提高抗生素研發的效率和效果，進一步提振了抗生素市場的前景。基因組學和高通量篩檢能夠識別潛在的藥物標靶並篩檢大規模化合物庫。許多公司都在投資這些技術。例如，2021年1月，輝瑞宣布透過其「輝瑞突破性舉措」（PBGI）向四家處於臨床階段的生物技術公司投資1.2億美元。這項合作旨在推動符合輝瑞未來戰略利益的、前景看好的臨床開發項目。電腦輔助藥物設計也使得預測藥物療效和最佳化候選抗生素成為可能。這些技術進步正在簡化抗生素的研發流程，與傳統方法相比，能夠節省時間和成本。此外，快速病原體鑑定和藥敏試驗等診斷技術的進步也有助於選擇合適的抗生素並改善患者的治療效果。

疾病負擔、抗菌素抗藥性和區域差異導致需求增加

由於全球健康壓力日益增加，市場正經歷穩定成長。感染疾病，尤其是在中低收入國家，盛行率的上升推動了頻譜抗生素需求的成長。產業報告顯示，2023年新增結核病病例約820萬例，高於2022年的750萬例。呼吸道感染疾病、尿道感染和胃腸道疾病仍然十分常見，導致全球醫療系統依賴抗生素作為第一線治療。同時，抗生素抗藥性正成為一個嚴重的全球性問題，降低了傳統治療方法的療效，並促使人們開發新的藥物類別。對第一線抗生素抗藥性的增強導致治療失敗和住院時間延長。這推動了公共和私人部門對新化合物和診斷技術改進的投資。此外，抗生素的使用和可近性存在顯著的地域差異。高所得國家重視監測和合理使用，而許多中低收入地區則面臨取得途徑有限、品質參差不齊和濫用等挑戰。這種不平衡進一步加劇了全球市場政策和供應鏈策略的複雜性。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球抗生素市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依作用機制分類

  • 細胞壁合成抑制劑
  • 蛋白質合成抑制劑
  • DNA合成抑制劑
  • RNA合成抑制劑
  • 分枝菌酸抑制劑
  • 其他

第7章 市場區隔：依藥物類別分類

  • 頭孢菌素
  • 青黴素
  • Fluoroquinolones
  • 大環內酯類
  • 碳青黴烯類
  • Aminoglycosides
  • 其他

第8章 市場區隔：依抗菌頻譜分類

  • 廣效抗生素
  • 窄譜抗生素

第9章 市場區隔：依給藥途徑

  • 口服
  • 腸外
  • 外用
  • 其他

第10章 市場區隔：依最終用戶分類

  • 醫院
  • 專科診所
  • 其他

第11章 市場區隔：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章 SWOT 分析

第13章：價值鏈分析

第14章：波特五力分析

第15章：價格分析

第16章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Allergan Plc（AbbVie Inc.）
    • Basilea Pharmaceutica AG
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Melinta Therapeutics
    • Merck & Co. Inc.
    • Nabriva Therapeutics Plc
    • Paratek Pharmaceuticals Inc.
    • Pfizer Inc.
    • Sanofi SA
    • Spero Therapeutics
    • Tetraphase Pharmaceuticals
Product Code: SR112026A3569

The global antibiotics market size was valued at USD 55.0 Billion in 2025. The market is projected to reach USD 74.3 Billion by 2034, exhibiting a CAGR of 3.28% during 2026-2034. Asia Pacific currently dominates the market, holding a significant market share of around 44% in 2025. The market is fueled by the increasing cases of pneumonia, tuberculosis, and other infectious diseases among individuals. The increasing concerns over antimicrobial resistance are driving the development of new and more effective antibiotic therapies. Also, expanding healthcare access in developing regions is supporting greater antibiotic consumption. In addition to this, continual technological advancements in biotechnology and drug discovery techniques are some of the major factors augmenting the antibiotics market share.

Currently, the increasing prevalence of chronic diseases in the global population is contributing to the market growth. Moreover, the widespread availability of antibiotics through online and offline stores and increased demand for topical antibiotics are boosting the product demand. Antibiotics help reduce the risk of infection in the surgical wound area for individuals. This has strengthened the global demand for antibiotics. Rising employment of antibiotics for the health and welfare of livestock animals is also fueling the market growth. In addition, the increased consumer awareness of preventative health care measures and growing demand in aging population are supporting the antibiotics market growth.

The antibiotics market in the United States is witnessing lucrative growth, fueled by the ongoing need to treat bacterial infections and the growing issue of antibiotic resistance. Investments in research and government-backed initiatives are encouraging the development of more effective treatments. A notable example is the FDA's approval in April 2023 of Zevtera (ceftobiprole medocaril sodium for injection), which is designed to treat Staphylococcus aureus bloodstream infections (bacteremia), including right-sided infective endocarditis and acute bacterial skin infections.

ANTIBIOTICS MARKET TRENDS:

Rising Incidence of Infectious Diseases

Worldwide, the incidence of infectious diseases such as pneumonia, tuberculosis, urinary tract infections (UTI), gastrointestinal infections and sepsis in the bloodstream is increasing among the population and people suffer more from these diseases because of inadequate sanitation. This contributes to the spread of bacterial infections. 10 out of 25 women and 3 out of 25 men have a urinary tract infection at some point in their lives. More powerful antibiotics are needed to help treat these infections. Antibiotics are specifically designed to target and eliminate bacterial infections. They effectively kill bacteria in the body and promote healing. Antibiotics are also used under the guidance of a health professional to optimize patient outcomes.

Increasing Occurrence of Antimicrobial Resistance (AMR)

There is a rise in the occurrence of antimicrobial resistance (AMR) across the globe, which is driving the antibiotics market. AMR occurs when bacteria, viruses, parasites, or fungi evolve and become resistant to the drugs used to treat them. It reduces the effectiveness of antibiotics and causes longer and more severe infections, increased healthcare costs, and high mortality rates among individuals. In 2019, bacterial antimicrobial resistance (AMR) was directly linked to 1.27 million deaths worldwide. Overuse and misuse of antibiotics are contributing to the development of drug-resistant bacteria, which makes traditional antibiotics less effective. In addition, multidrug-resistant strains, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE), are more prevalent. This necessitates the sales and development of advanced antibiotics, thereby contributing to the market growth.

Technological Advancements in Antibiotics

Innovations in biotechnology, molecular biology, and drug discovery techniques are helping to improve the efficiency and effectiveness of antibiotic development. This, in turn, is enhancing the antibiotics market outlook. Genomics and high-throughput screening enable the identification of potential drug targets and the screening of large compound libraries. Many companies are investing in the technology. For example, in January 2021, Pfizer Inc. announced a $120 million investment in four clinical-stage biotechnology companies under the Pfizer Breakthrough Growth Initiative (PBGI). The partnership aims to advance promising clinical development programs in line with Pfizer's future strategic interests. Computer-aided drug design also allows for predicting drug efficacy and optimizing antibiotic candidates. These technological advances have streamlined the antibiotic discovery process and reduce the time and costs compared to traditional methods. In addition, advances in diagnostic techniques, such as rapid pathogen identification and sensitivity testing, help in choosing the right antibiotic to improve patient outcomes.

Rising Demand due to Disease Burden, Resistance, and Regional Disparities

The market is experiencing steady growth due to increasing global health pressures. The rising prevalence of infectious diseases, particularly in low- and middle-income countries, is driving higher demand for broad-spectrum antibiotics. Industry reports indicate that approximately 8.2 million new tuberculosis cases were recorded in 2023, reflecting an increase from 7.5 million cases in 2022. Respiratory infections, urinary tract infections, and gastrointestinal disorders remain especially common, prompting healthcare systems worldwide to rely on antibiotics as frontline therapy. Concurrently, antimicrobial resistance is intensifying worldwide, reducing the effectiveness of older treatments and forcing the development of new drug classes. Resistance to first-line antibiotics has increased, leading to treatment failures and longer hospital stays. This has spurred public and private sector investments in novel compounds and improved diagnostics. Moreover, the geographic distribution of antibiotic usage and access varies significantly. High-income countries emphasize surveillance and stewardship, while many low- and middle-income regions face limited access, inconsistent quality, and misuse. This imbalance adds complexity to policy and supply chain strategies across the global market.

ANTIBIOTICS INDUSTRY SEGMENTATION:

Analysis by Action Mechanism:

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • Others

Cell wall synthesis inhibitors action mechanism is the largest action mechanism in 2025, holding around 52% market share. Cell wall synthesis inhibitors is a class of antibiotics that target the bacterial cell wall. These antibiotics interfere with the process of cell wall synthesis, which causes cell wall damage and eventual bacterial death. In addition, penicillin, cephalosporins, and carbapenems are some of the cell wall synthesis inhibitors. They work by inhibiting enzymes called penicillin-binding proteins (PBPs) that are involved in the cross-linking of peptidoglycan chains. Moreover, cell wall synthesis inhibitors are particularly effective against gram-positive bacteria due to their thicker peptidoglycan layer, which provides a greater target for disruption.

Analysis by Drug Class:

  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolide
  • Carbapenem
  • Aminoglycoside
  • Others

Penicillin leads the market with around 26% market share in 2025. As per antibiotics market report segmentation, Penicillin is a widely used class of antibiotics that belongs to the beta-lactam drug class. It works by inhibiting the synthesis of bacterial cell walls that causes cell wall damage and bacterial death. It is considered an essential medicine and is widely available as generic drugs. Apart from this, it is increasingly used in various healthcare settings, such as hospitals, clinics, and outpatient settings. In addition, the rising utilization of penicillin, as it is effective against various bacterial infections, is contributing to the growth of the market.

Analysis by Activity:

  • Broad-Spectrum Antibiotics
  • Narrow-Spectrum Antibiotics

Broad-spectrum antibiotics segment leads the market with around 70% market share in 2025. Broad-spectrum antibiotics are a class of antibiotics that exhibit activity against a wide range of bacteria, such as gram-positive and gram-negative bacteria. In line with this, the rising adoption of broader spectrum antibiotics, as they are effective against a broader range of microorganisms compared to narrow-spectrum antibiotics, is bolstering the growth of the market. Apart from this, broad-spectrum antibiotics assist in treating infections when the causative bacteria are unknown or when the infection involves multiple bacterial species. The appropriate use of broad-spectrum antibiotics minimizes the risks of infections in the body.

Analysis by Route of Administration:

  • Oral
  • Parenteral
  • Topical
  • Others

Parenteral leads the market with over 68% market share in 2025. Parenteral antibiotics are administered via routes other than the digestive tract, such as intravenous (IV), intramuscular (IM), or subcutaneous (SC) routes. These routes allow for direct delivery of the medication into the bloodstream or deep tissues, bypassing the gastrointestinal system. In addition, parenteral antibiotics provide rapid and predictable drug absorption and immediate therapeutic effect. They are also suitable for patients with compromised gastrointestinal function. Apart from this, it allows for accurate dosing and is particularly beneficial in cases where high drug concentrations are needed or when oral administration is not possible.

Analysis by End User:

  • Hospitals
  • Specialty Clinics
  • Others

Hospitals leads the market with around 60% market share in 2025. Antibiotics are widely consumed in hospitals due to the increased number of patients staying in this healthcare setting. Antibiotics are administered to patients admitted with severe infections. They are also administered before surgical procedures to reduce the risk of bacterial contamination. In line with this, the rising utilization of antibiotics among individual post-surgical prophylaxis is contributing to the growth of the market. Apart from this, the increasing consumption of antibiotics due to the rising risk of multidrug-resistant infections in hospitals is supporting the growth of the market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2025, Asia-Pacific accounted for the largest market share of around 44%. The growing incidence of bacterial infections to poor sanitation is contributing to the growth of the market in the Asia Pacific region. Apart from this, the increasing demand for advanced antibiotics that can effectively combat multidrug-resistant bacteria is supporting the growth of the market. Furthermore, the presence of a large number of generic drug manufacturers is propelling the growth of the market in the region.

KEY REGIONAL TAKEAWAYS:

NORTH AMERICA ANTIBIOTICS MARKET ANALYSIS:

The North America antibiotics market is driven by the increasing incidence of infectious diseases, particularly respiratory infections, and urinary tract infections, as these conditions necessitate effective antibiotic treatments to combat rising bacterial resistance. Additionally, the aging population in the region contributes to heightened demand for antibiotics, as older adults are more susceptible to infections. Advances in antibiotic development, including novel formulations and combination therapies, are also critical in addressing antibiotic resistance challenges. Furthermore, strategic collaborations among pharmaceutical companies and increased investment in research and development are enhancing the pipeline of new antibiotics, ensuring the market remains responsive to evolving health needs.

UNITED STATES ANTIBIOTICS MARKET ANALYSIS:

United States accrued a market share of around 86% in the North America market in 2024. The increased incidence of bacterial illnesses, improvements in healthcare facilities, and significant R&D expenditures are the main factors propelling the U.S. antibiotics industry. Urinary tract infections and respiratory tract infections continued to be among the most frequently treated illnesses in 2023, which increased the need for a wide range of antibiotics. The market is greatly influenced by the aging population, which is expected to reach more than 78 million by 2040 and more than 88 million by 2060. This is because older people are more prone to illnesses. Also, one of the significant antibiotics market trends is the rise of strains of bacteria that are resistant to antibiotics, like MRSA, which is increasing the demand for next-generation antibiotics and sparked innovation in the pharmaceutical industry.

Research on new antibiotic classes and quick diagnostics are supported by government programs to address antimicrobial resistance (AMR), such as the National Action Plan for Combating Antibiotic-Resistant Bacteria. Additionally, market expansion is driven by the FDA's accelerated approval processes for important medicines and the robust presence of major pharmaceutical companies in the United States. Demand is being further fueled by healthcare facilities implementing stricter antibiotic regimens in response to an increase in hospital-acquired infections (HAIs). The U.S. market for antibiotics is expanding despite issues with overuse and resistance, owing to strong healthcare spending and innovation.

EUROPE ANTIBIOTICS MARKET ANALYSIS:

The growing cases of infectious diseases and the numerous government programs designed to fight antibiotic resistance are the main factors affecting the antibiotics market in Europe. According to the World Health Organization (WHO), Europe uses a diverse range of antibiotics and has a high rate of resistant bacterial strains, including Klebsiella pneumonia and E. coli. As a result, the players are investing in the creation of novel antibiotics and stewardship initiatives to maximize their use.

Leading countries in this sector include Germany, France, and the United Kingdom, bolstered by their sophisticated healthcare systems and proactive AMR regulations. Additionally, the EMA has expedited the approval procedures for antibiotics that fulfill unmet medical requirements. The increase of outpatient care services and the increasing use of quick diagnostic techniques for bacterial infections are driving the market demand further.

ASIA PACIFIC ANTIBIOTICS MARKET ANALYSIS:

The high incidence of infectious diseases, rising healthcare costs, and growing awareness of contemporary treatments are all contributing to the Asia-Pacific antibiotics market's rapid expansion. Antibiotic demand is fueled by the high incidence of bacterial illnesses, such as pneumonia and tuberculosis, in nations like China, Indonesia, and India. According to time-series research, a total of 16,290 million doses of antibiotics were sold in India in 2020, which is slightly less than the amount in 2018 and 2019. Apart from this, the antibiotics market worth is further increased by the expanding middle class and better access to healthcare services in emerging markets.

The region's governments are tackling issues such as antibiotic resistance by supporting antibiotic stewardship initiatives and providing funds for research into novel medication classes. As significant producers of antibiotics, China and India also gain from export prospects. Additionally, the use of telemedicine platforms is expanding the availability of antibiotic treatments in remote locations.

LATIN AMERICA ANTIBIOTICS MARKET ANALYSIS:

The incidence of infectious disorders, such as gastrointestinal and respiratory infections, is propelling the Latin American market growth. Advanced antibiotics are being adopted by nations like Brazil and Mexico to fight infections that are worsened by inadequate access to healthcare and poor sanitation. The industry is expanding owing to government programs like vaccination campaigns that use preventative antibiotics and investments in healthcare infrastructure. Furthermore, the region's expanding pharmaceutical sector and collaborations with international pharmaceutical companies are opportunistic for the market growth.

MIDDLE EAST AND AFRICA ANTIBIOTICS MARKET ANALYSIS:

The high incidence of infectious diseases, including respiratory infections, malaria, and tuberculosis, has an impact on the demand for antibiotics. Antibiotics are becoming more widely available in the Middle East due to the investments made in healthcare modernization by nations like Saudi Arabia and the United Arab Emirates. International agencies like UNICEF and WHO are assisting antibiotic supply chains in Africa to address healthcare issues. While government programs are encouraging local production to lessen reliance on imports, awareness campaigns and measures to combat antibiotic resistance are gradually improving usage patterns.

COMPETITIVE LANDSCAPE:

Key players in the industry are investing in research and development (R&D) activities to discover and develop new antibiotics and focus on antibiotic resistance, expanding the spectrum of activity, and improving the efficacy and safety profiles of antibiotics. Apart from this, they are engaging in collaboration with research institutions, academic organizations, and government bodies to leverage their expertise and address the challenges associated with antibiotic development, such as high costs and regulatory compliances. Moreover, antibiotic companies are actively promoting antibiotic stewardship programs that encourage responsible and appropriate use of antibiotics to avoid overdosage and misuse. According to antibiotics market research report, companies are increasingly conducting clinical trials and adhering to safety and efficacy standards to obtain regulatory approvals for their antibiotics.

The report provides a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Allergan Plc (AbbVie Inc.)
  • Basilea Pharmaceutica AG
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Melinta Therapeutics
  • Merck & Co. Inc.
  • Nabriva Therapeutics Plc
  • Paratek Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Spero Therapeutics
  • Tetraphase Pharmaceuticals

Key Questions Answered in This Report

  • 1.How big is the antibiotics market?
  • 2.What is the future outlook of the antibiotics market?
  • 3.What are the key factors driving the antibiotics market?
  • 4.Which region accounts for the largest antibiotics market share?
  • 5.Which are the leading companies in the global antibiotics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Antibiotics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Action Mechanism

  • 6.1 Cell Wall Synthesis Inhibitors
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Protein Synthesis Inhibitors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 DNA Synthesis Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 RNA Synthesis Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Mycolic Acid Inhibitors
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Cephalosporin
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Penicillin
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Fluoroquinolone
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Macrolide
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Carbapenem
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Aminoglycoside
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Spectrum of Activity

  • 8.1 Broad-Spectrum Antibiotics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Narrow-Spectrum Antibiotics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Topical
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by End User

  • 10.1 Hospitals
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Specialty Clinics
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Others
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Allergan Plc (AbbVie Inc.)
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 SWOT Analysis
    • 16.3.2 Basilea Pharmaceutica AG
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 GlaxoSmithKline Plc
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Johnson & Johnson
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
      • 16.3.4.4 SWOT Analysis
    • 16.3.5 Melinta Therapeutics
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
    • 16.3.6 Merck & Co. Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Nabriva Therapeutics Plc
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
    • 16.3.8 Paratek Pharmaceuticals Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
    • 16.3.9 Pfizer Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Sanofi SA
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Spero Therapeutics
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
    • 16.3.12 Tetraphase Pharmaceuticals
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio

List of Figures

  • Figure 1: Global: Antibiotics Market: Major Drivers and Challenges
  • Figure 2: Global: Antibiotics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Antibiotics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Antibiotics Market: Breakup by Action Mechanism (in %), 2025
  • Figure 5: Global: Antibiotics Market: Breakup by Drug Class (in %), 2025
  • Figure 6: Global: Antibiotics Market: Breakup by Spectrum of Activity (in %), 2025
  • Figure 7: Global: Antibiotics Market: Breakup by Route of Administration (in %), 2025
  • Figure 8: Global: Antibiotics Market: Breakup by End User (in %), 2025
  • Figure 9: Global: Antibiotics Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Antibiotics (Cell Wall Synthesis Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Antibiotics (Cell Wall Synthesis Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Antibiotics (Protein Synthesis Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Antibiotics (Protein Synthesis Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Antibiotics (DNA Synthesis Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Antibiotics (DNA Synthesis Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Antibiotics (RNA Synthesis Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Antibiotics (RNA Synthesis Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Antibiotics (Mycolic Acid Inhibitors) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Antibiotics (Mycolic Acid Inhibitors) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Antibiotics (Other Action Mechanisms) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Antibiotics (Other Action Mechanisms) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Antibiotics (Cephalosporin) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Antibiotics (Cephalosporin) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Antibiotics (Penicillin) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Antibiotics (Penicillin) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Antibiotics (Fluoroquinolone) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Antibiotics (Fluoroquinolone) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Antibiotics (Macrolide) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Antibiotics (Macrolide) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Antibiotics (Carbapenem) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Antibiotics (Carbapenem) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Antibiotics (Aminoglycoside) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Antibiotics (Aminoglycoside) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Antibiotics (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Antibiotics (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Antibiotics (Broad-Spectrum Antibiotics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Antibiotics (Broad-Spectrum Antibiotics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Antibiotics (Narrow-Spectrum Antibiotics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Antibiotics (Narrow-Spectrum Antibiotics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Antibiotics (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Antibiotics (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Global: Antibiotics (Parenteral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Global: Antibiotics (Parenteral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Global: Antibiotics (Topical) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Global: Antibiotics (Topical) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Global: Antibiotics (Other Routes of Administration) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Global: Antibiotics (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Global: Antibiotics (Hospitals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Global: Antibiotics (Hospitals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Global: Antibiotics (Specialty Clinics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Global: Antibiotics (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Global: Antibiotics (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Global: Antibiotics (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: North America: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: North America: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: United States: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: United States: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Canada: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Canada: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Asia-Pacific: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Asia-Pacific: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: China: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: China: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Japan: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Japan: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: India: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: India: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: South Korea: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: South Korea: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Australia: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Australia: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Indonesia: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Indonesia: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Others: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Others: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Europe: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Europe: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Germany: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Germany: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: France: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: France: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: United Kingdom: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: United Kingdom: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Italy: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Italy: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Spain: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Spain: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Russia: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: Russia: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 90: Others: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 91: Others: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 92: Latin America: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 93: Latin America: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 94: Brazil: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 95: Brazil: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 96: Mexico: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 97: Mexico: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 98: Others: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 99: Others: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 100: Middle East and Africa: Antibiotics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 101: Middle East and Africa: Antibiotics Market: Breakup by Country (in %), 2025
  • Figure 102: Middle East and Africa: Antibiotics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 103: Global: Antibiotics Industry: SWOT Analysis
  • Figure 104: Global: Antibiotics Industry: Value Chain Analysis
  • Figure 105: Global: Antibiotics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Antibiotics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Antibiotics Market Forecast: Breakup by Action Mechanism (in Million USD), 2026-2034
  • Table 3: Global: Antibiotics Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 4: Global: Antibiotics Market Forecast: Breakup by Spectrum of Activity (in Million USD), 2026-2034
  • Table 5: Global: Antibiotics Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 6: Global: Antibiotics Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 7: Global: Antibiotics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Antibiotics Market: Competitive Structure
  • Table 9: Global: Antibiotics Market: Key Players